ArticlePharmaceutical research2026
Screening of Unexplored FDA-approved Inactive Ingredients as Stabilizers for Monoclonal Antibody Products.
Article in Pharmaceutical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeMonoclonal antibodies (mAbs) are susceptible to physical and chemical degradation, which can compromise product quality, efficacy, safety, and shelf life. Although excipients play a critical role in stabilizing mAb formulations, only a limited number are routinely used in marketed products. Therefore, this study aimed to identify underexplored FDA-approved inactive ingredients with the potential to stabilize mAb formulations.
methodsFourteen FDA-approved inactive ingredients were screened using a size-exclusion chromatography (SEC)-based comparative forced-degradation approach. Trastuzumab was used as the model IgG1 antibody and subjected to thermal stress at 70°C and 65°C. Candidate excipients were evaluated through concentration optimization, SEC-HPLC, fluorescence spectroscopy, UV-vis spectroscopy, differential scanning calorimetry, surface plasmon resonance, haemolysis assays, and molecular docking.
resultsInitial screening identified isomalt and myo-inositol as the most effective excipients, reducing high-molecular-weight species by up to 60%, whereas choline chloride produced a smaller but measurable reduction. Optimized concentrations of 400 mM isomalt, 150 mM myo-inositol, and 1.9 mM choline chloride reduced aggregation, preserved monomer content, and improved higher-order structural stability. These formulations retained HER2 and FcRn binding and exhibited haemolysis below 3% compared to PS80 containing mAb sample. Isomalt also improved the thermal stability of adalimumab and rituximab, while molecular docking suggested preferential association with aggregation-prone regions of the trastuzumab Fab domain.
conclusionsUnderexplored FDA-approved excipients, particularly isomalt and myo-inositol, improved mAb stability under thermal stress and represent promising candidates for further evaluation during therapeutic antibody formulation development.
Indexed as
Identifiers
42864475What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.